Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Overwhelming Medicare Plan Choices Spell Confusion
In a sign of the challenges facing seniors on Medicare, a new study finds that older Americans are more likely to make poor choices when faced with a wide array of drug-coverage plans. Making matters worse, many are confident they made the right decisions.
generic viagra online
Health Information Technology Lobby Group Rallies Support For Certification Group; Critics Question Group's Ties
The Healthcare Information and Management Systems Society has asked HHS to give the Certification Commission for Healthcare Information Technology authorization to determine which electronic health records systems can receive funding from the economic stimulus package, the Washington Post reports. In a letter dated April 27 to HHS officials, HIMSS officials wrote, "To ensure continuity, recognize CCHIT as the certifying body" of EHRs.Some health care industry officials have raised issue with giving CCHIT the responsibility of certifying EHR products because of the commission"s associations with various IT and health care companies, the Post reports. CCHIT has ties with HIMSS, which played a role in its inception in 2004 and is now managed by Mark Leavitt, the former chief medical officer of HIMSS. In 2005, the commission received a three-year, $7.5 million contract from HHS.According the Post, Internal Revenue Service tax documents show that HIMSS technically paid Leavitt"s salary through 2008, which was reimbursed by CCHIT. However, Leavitt said he is accountable only to CCHIT"s board members and he "was not supervised by HIMSS." He said he expects CCHIT will be "the body or one of several certifying bodies that are recognized" by HHS in part because it already is tasked with certifying health IT products. According to Leavitt, some of the commission"s critics are IT vendors who have failed to meet CCHIT"s standards. The Post reports that the provision in the stimulus package that requires health care providers to demonstrate "meaningful use" of health IT has become an issue because federal officials, IT systems vendors, and physicians and patient advocates have not been able to reach a consensus on the definition of meaningful use. Under the provision, providers must demonstrate meaningful use of health IT in order to receive Medicare and Medicaid incentive payments for adopting the technology (O"Harrow, Washington Post, 5/21). Blumenthal
News of the day
Secret Plans To Criminalize Generic Medicines Could Hurt Poor Countries And People
International agency Oxfam fears that companies producing affordable generic medicines could be subject to criminal prosecutions and have their medicines seized on orders from big drug companies under plans being drawn up by a closed group of mainly rich countries.
Medical Devices

New Johns Hopkins Study Betters The Odds Of Success In Predicting The Return Of Prostate Cancer

Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis. The new prediction method comprises the length of time it takes for PSA (prostate-specific antigen) to double, Gleason score (a numeric indicator of prostate cancer aggressiveness as seen under the microscope), and the interval between surgical removal of the prostate and the first detectable PSA level. According to Johns Hopkins investigators, combining these three measurements more accurately estimates risk that the cancer has spread than do other methods and should help determine which patients may benefit from additional therapy when PSA levels rise after surgery to remove the prostate. Findings from the study presented at the June 2009 annual meeting of the American Society of Clinical Oncology (ASCO) may also help resolve the debate on when and in what form secondary treatments should occur. "There is much debate on whether to prescribe immediate treatment for a man whose PSA begins to rise after he has had prostate cancer surgery, or to delay it," says Emmanuel Antonarakis, M.D., Johns Hopkins Kimmel Cancer Center investigator. "Studies suggest that most men live the same length of time overall whether they receive therapy at the first sign of a rising PSA or wait until the cancer has spread to other sites." After reviewing the records of 774 men whose PSA rose after surgery to remove the prostate, the researchers found that Gleason score and two measurements for PSA were the strongest risk factors for prostate cancer metastasis. Men with Gleason scores in the highest range, between eight and 10, were twice as likely to develop metastatic cancer. In men whose PSA became detectable within three years after surgery, cancer was more than three times more likely to spread to other organs. Finally, men whose PSA doubled the fastest, within three months, were more than 20 times more likely to develop metastatic cancer than men whose PSA look longer than 15 months to double. For men enrolled in the study, it took a median of 10 years for the disease to reappear on imaging scans. "The 10-year average will not apply to every man, so we wanted to know what factors put men at higher risk for their cancer progressing earlier," says Mario Eisenberger, M.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center. An increase in PSA, or prostate specific antigen, occurs in approximately 20 percent to 30 percent of men after surgery to remove the cancerous prostate, says Antonarakis. In these patients, the newly emerging prostate cancer cells are rarely detectable on imaging scans. When faced with the likelihood that their cancer has spread, many men opt to undergo hormone therapy, which blocks testosterone production, a fuel for prostate cancer. The side effects, which mimic those of menopausal women, include hot flashes, night sweats, osteoporosis, metabolic syndrome and coronary disease, and can be debilitating, says Antonarakis. Besides immediate hormone therapy, other options for men whose PSA is rising are to use hormone therapy intermittently, enroll in clinical trials testing experimental therapies or combinations of them, or to "watch and wait" until imaging scans can locate metastatic disease. Notes: Data on the prostate cancer patients involved in this study were collected from a database maintained by Patrick C. Walsh, M.D., at the Johns Hopkins Brady Urological Institute. The information spans nearly 20 years of patient records at Johns Hopkins. The research was funded by the National Cancer Institute, the Prostate Cancer Foundation, and the Department of Defense Prostate Cancer Research Program. In addition to Antonarakis and Eisenberger, the following researchers participated in the study: Bruce Trock, Zhaoyong Feng, Elizabeth Humphreys, Michael Carducci, Alan Partin, and Patrick Walsh from Johns Hopkins. Amy Mone Johns Hopkins Medical Institutions


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009